Archive for February, 2010

Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race

Annals of Internal Medicine  June 2003 V.138  N.12  p.960-968

Jane E. Sisk, PhD; William Whang, MD, MS; Jay C. Butler, MD; Vishnu-Priya Sneller, MBBS, PhD; and Cynthia G. Whitney, MD, MPH

From the Mount Sinai School of Medicine and Mailman School of Public Health, Columbia University, New York, New York; Massachusetts General Hospital, Boston, Massachusetts; and Centers for Disease Control and Prevention, Anchorage, Alaska, and Atlanta, Georgia.

Background

Guidelines are increasingly recommending preventive services starting at 50 years of age, and policymakers are considering such a recommendation for pneumococcal polysaccharide vaccination. The finding that pneumococcal vaccination is cost-saving for people 65 years of age or older raises the question of the vaccination’s implications for other older adults, especially black people, whose disease incidence exceeds that of nonblack people, and those with high-risk conditions.

Objective

To assess the implications of vaccinating black and nonblack people 50 through 64 years of age against invasive pneumococcal disease.

Design

Cost-effectiveness analysis.

Data Sources

Published literature for vaccination effectiveness and cost estimates; data on disease incidence and case-fatality rates from the Centers for Disease Control and Prevention.

Target Population

Hypothetical cohort 50 through 64 years of age with the 1995 U.S. age distribution.

Time Horizon

Lifetime.

Perspective

Societal.

Intervention

Pneumococcal polysaccharide vaccination compared with no vaccination.

Outcome Measures

Incremental medical costs and health effects, in quality-adjusted life-years per vaccinee.

Results of Base-Case Analysis

Vaccination saved medical costs and improved health among high-risk black people ($27.55 savings per vaccinee) and nonblack people ($5.92 savings per vaccinee), excluding survivors’ future costs. For low-risk black and nonblack people and the overall general population, vaccination cost $2477, $8195, and $3434, respectively, to gain 1 year of healthy life.

Results of Sensitivity Analysis

Excluding survivors’ future costs, in the general immunocompetent population, cost per quality-adjusted life-year in global worst-case results ranged from $21 513 for black people to $68 871 for nonblack people; in the high-risk population, cost ranged from $11 548 for black people to $39 000 for nonblack people. In the global best case, vaccination was cost-saving for black and nonblack people in the general immunocompetent and high-risk populations, excluding survivors’ future costs. The cost-effectiveness range was narrower in probabilistic sensitivity analyses, with 95% probabilistic intervals ranging from cost-saving to $1594 for black people and from cost-saving to $12 273 for nonblack people in the general immunocompetent population. Costs per quality-adjusted life-year for low-risk people with case-fatality rates from 1998 were $2477 for black people and $8195 for nonblack people, excluding survivors’ medical costs.

Conclusions

These results support the current recommendation to vaccinate high-risk people and provide useful information for considering extending the recommendation to the general population 50 through 64 years of age. Lack of evidence about the effectiveness of revaccination for people 65 years of age or older, when disease risks are higher, argues for further research to guide vaccination policy.

abstract

http://www.annals.org/content/138/12/960.abstract

PDF

http://www.annals.org/content/138/12/960.full.pdf+html

Advertisements

February 27, 2010 at 4:25 pm Leave a comment

Outbreak of 2009 Pandemic Influenza A (H1N1) on a Peruvian Navy Ship — June–July 2009

MMWR Weekly  February 19, 2010  V.59  N.6 p.162-165

On June 25, 2009, a naval cadet reported to the infirmary of a 355-crewman Peruvian Navy ship with a febrile acute respiratory infection (FARI) 5 days after the ship docked in San Francisco, California. Pandemic 2009 influenza A (H1N1) virus was suspected as the cause because it was circulating in the city at that time. A test for pandemic H1N1 by real-time reverse transcription–polymerase chain reaction (rRT-PCR) was positive. During the subsequent 3 weeks, as the ship continued its cruise, 77 additional crew members developed confirmed pandemic H1N1 influenza. The U.S. Naval Medical Research Center Detachment (NMRCD), in collaboration with the Peruvian Navy, conducted an investigation to describe the outbreak and determine the attack rate for pandemic H1N1 influenza on the ship. This report summarizes the results of that investigation, which indicated that, of the 85 patients with FARI, 78 (92%) tested positive for pandemic H1N1 by rRT-PCR. The attack rate for confirmed pandemic H1N1 influenza was 22.0%. The most frequent symptoms …

Full Text

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5906a3.htm?s_cid=mm5906a3_e

PDF (ver p.162)

http://www.cdc.gov/mmwr/pdf/wk/mm5906.pdf

February 27, 2010 at 3:25 pm Leave a comment

Guillain-Barré Syndrome Among Recipients of Menactra® Meningococcal Conjugate Vaccine — United States, June–July 2005

MMWR  October 14, 2005   V.54  N.40  P. 1023-1025

On October 6, this report was posted as an MMWR Dispatch on the MMWR website (http://www.cdc.gov/mmwr).

On January 14, 2005, a quadrivalent (A, C, Y, and W135) meningococcal conjugate vaccine (Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Menactra®, Sanofi-Pasteur, Swiftwater, Pennsylvania) (MCV4) was licensed in the United States. MCV4 is a tetravalent vaccine; each 0.5-mL dose contains 4 µg each of capsular polysaccharide from Neisseria meningitidis serogroups A, C, Y, and W-135 conjugated to 48 µg of diphtheria toxoid. In February 2005, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of adolescents at the preadolescent health-care visit (at ages 11–12 years) (1). For persons who have not been vaccinated previously, ACIP recommended vaccination before …

Full Text

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5440a6.htm

PDF

http://www.cdc.gov/mmwr/PDF/wk/mm5440.pdf

February 27, 2010 at 3:16 pm Leave a comment

Preventing Pneumococcal Disease Among Infants and Young Children

MMWR October 6, 2000   V.49  N.RR 9   P. 1 – 38

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Advisory Committee on Immunization Practices

Membership List, June 2000

Full text

http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4909a1.htm

PDF

http://www.cdc.gov/mmwr/PDF/rr/rr4909.pdf

February 27, 2010 at 3:10 pm Leave a comment

Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease

MMWR  September 25, 2009  V.58  N.37  p.1042-1043

The Advisory Committee on Immunization Practices (ACIP) recommends quadrivalent meningococcal conjugate vaccine, (MCV4) (Menactra, Sanofi Pasteur, Swiftwater, Pennsylvania) for all persons aged 11–18 years and for persons aged 2–55 years at increased risk for meningococcal disease (1–3). MCV4 is licensed as a single dose. Because of the high risk for meningococcal disease among certain groups and limited data on duration of protection, at its June 2009 meeting ACIP recommended that persons previously vaccinated with either MCV4 or MPSV4 (Menomune, Sanofi Pasteur) who are at prolonged increased risk for meningococcal disease should be revaccinated with MCV4. Persons who previously were vaccinated at age ≥7 years and are at prolonged increased risk should be revaccinated 5 years after their previous meningococcal vaccine, and persons who previously were vaccinated at ages 2–6 years and are at prolonged increased risk should be revaccinated 3 years after their previous meningococcal vaccine. Persons at prolonged increased risk for …

Full Text

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm

PDF

http://www.cdc.gov/mmwr/pdf/wk/mm5837.pdf

February 27, 2010 at 3:05 pm Leave a comment

Intravenous and Inhalational Colistin–Induced Respiratory Failure

Clinical Infectious Diseases  15 March 2010  V.50  N.6  e38–e40

BRIEF REPORT

Krista Wahby,1 Teena Chopra,2 and Pranatharthi Chandrasekar2

1Pharmacy Department, Harper University Hospital/Hutzel Women’s Hospital, Detroit Medical Center, Wayne State University, and 2Division of Infectious Diseases, Harper University Hospital, Wayne State University/Karmanos Cancer Institute Detroit, Michigan

The emergence of highly resistant gram-negative pathogens in hospitals around the world has placed emphasis on colistin, a seemingly ancient drug. Respiratory failure from colistin was reported in the years following its release; however, there are no recent reports of colistin-induced respiratory failure. We report a case of intravenous colistin– and, later, inhalational colistin–induced respiratory failure.

abstract

http://www.journals.uchicago.edu/doi/abs/10.1086/650582

PDF

http://www.journals.uchicago.edu/doi/pdf/10.1086/650582

February 26, 2010 at 6:21 pm Leave a comment

Fulminant Infectious Mononucleosis and Recurrent Epstein-Barr Virus Reactivation in an Adolescent

Clinical Infectious Diseases  15 March 2010  V.50  N.6  e34–e37

Jamie P. Nourse,1 Kimberley Jones,1 Ujjwal Dua,1 Naomi Runnegar,3 David Looke,3 Chris Schmidt,2

Siok-Keen Tey,5 Glen Kennedy,5,a and Maher K. Gandhi1,4,a

1Clinical Immunohaematology Laboratory and 2Cancer Immunotherapy Laboratory, Queensland Institute of Medical Research, Departments of 3Infectious Diseases and 4Haematology, Princess Alexandra Hospital, and 5Department of Haematology, Royal Brisbane Hospital, Brisbane, Australia

We describe a unique case of fulminant infectious mononucleosis and recurrent Epstein-Barr virus reactivation presenting in an adolescent. Detailed assays of Epstein-Barr virus–specific T cell immunity revealed defects in the patient’s T cell receptor signalling pathway characterized by a lack of interleukin-2 and CD25 expression, which may have contributed to her clinical course. Allogeneic stem cell transplantation reversed the clinical and laboratory phenotype.

abstract

http://www.journals.uchicago.edu/doi/abs/10.1086/650007

PDF

http://www.journals.uchicago.edu/doi/pdf/10.1086/650007

February 26, 2010 at 6:19 pm Leave a comment

Older Posts


Calendar

February 2010
M T W T F S S
« Jan   Mar »
1234567
891011121314
15161718192021
22232425262728

Posts by Month

Posts by Category